MetaCap

Attovia Therapeutics (ATTO) vs Solid Biosciences (SLDB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.

Summary

Attovia Therapeutics is the larger company by market cap ($749.6 million vs $734.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ATTO-25.02%SLDB-21.53%
+22%-3%-27%
Aug 5, 20261 yearOct 7, 2026
ATTO-18.59%SLDB-18.36%
+29%+4%-21%
Aug 3, 20265 yearsOct 5, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ATTO versus SLDB key metrics
MetricATTOSLDB
Share price$16.42$6.85
Market cap$749.59M$734.49M
1-day change-6.17%-1.01%
YTD return—+21.45%
1-year return—+24.09%
5-year return—-79.70%
EPS (TTM)$-2.74$-1.89
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$28.00$11.45
52-week low$16.15$3.79
Distance from 52-week high-41.36%-40.17%
Average volume456.94K1.10M
Shares outstanding45.65M107.23M
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

ATTO vs SLDB FAQ

Which is bigger, Attovia Therapeutics or Solid Biosciences?

Attovia Therapeutics (ATTO) is larger, with a market capitalization of $749.59M compared with $734.49M for Solid Biosciences (SLDB).

Are Attovia Therapeutics and Solid Biosciences in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons